Publikationer

Unprecedented 5-year survival data for newly diagnosed glioblastoma from the EF-14 trial published in JAMA

Effect of Tumor-Treating Fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial.

Journal of the American Medical Association

Stupp R, Taillibert S, Kanner A, et al. 2017;318(23):2306-2316.


Copyright 2017 American Medical Association. All rights reserved.

The EF-11 trial: Pivotal phase 3 data for recurrent glioblastoma published in the European Journal of Cancer

NovoTTF-100A versus physician’s choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality.

European Journal of Cancer


Stupp R, Wong ET, Kanner AA, et al. 2012;48(14):2192-2202.


Copyright 2012 Elsevier. All rights reserved.

Management of dermatologic adverse events


Prevention and management of dermatologic adverse events associated with Tumor Treating Fields in patients with glioblastoma.

Frontiers in Oncology


Lacouture ME, Anadkat MJ, Ballo MT, et al. 2020;10:1045. doi:10.3389/fonc.2020.01045.


Copyright © 2020 Lacouture, Anadkat, Ballo, Iwamoto, Jeyapalan, La Rocca, Schwartz, Serventi and Glas.

A meta-analysis evaluating OS in patients treated with TTFields


Association of Tumor Treating Fields (TTFields) therapy with survival in newly diagnosed glioblastoma: a systematic review and meta‑analysis

Journal of Neuro-Oncology


Ballo MT, Conlon P, Lavy-Shahaf G, Kinzel A, Vymazal J, Rulseh AM. 2023;164(1):1-9. doi:10.1007/s11060-023-04348-w

Subgroup analysis of the EF-14 trial


Increased compliance with tumor treating fields therapy is prognostic for improved survival in the treatment of glioblastoma: a subgroup analysis of the EF-14 phase III trial

Journal of Neuro-Oncology


Toms SA, Kim CY, Nicholas G, Ram Z. 2019;141(2):467-473. doi:10.1007/s11060-018-03057-z

Influence of TTFields on health-related quality of life


Influence of treatment with Tumor-Treating Fields on health-related quality of life of patients with newly diagnosed glioblastoma: a secondary analysis of a randomized clinical trial

JAMA Oncology


Taphoorn MJB, Dirven L, Kanner AA, et al. 2018;4(4):495-504.
© 2018 American Medical Association. All rights reserved.

Real-world health-related QOL outcomes

Health-related quality of life for patients receiving Tumor Treating Fields for glioblastoma.

Frontiers in Oncology

Palmer JD, Chavez G, Furnback W, et al. 2021;11:77226. doi:10.3389/fonc.2021.772261

Subgroup analysis of elderly patients in the EF-14 trial

Efficacy and safety of Tumor Treating Fields (TTFields) in elderly patients with newly diagnosed glioblastoma: subgroup analysis of the phase 3 EF-14 clinical trial.

Frontiers in Oncology

Ram Z, Kim C-Y, Hottinger AF, Idbaih A, Nicholas G, Zhu J-J. 2021;11:671972. doi:10.3389/fonc.2021.671972